Prime and Magellan Rx present at: AMCP Nexus 2023

Event/registration: AMCP Nexus 2023

Medically Integrated Dispensing Services: Creative Value for Payers and Providers

Date/time: Tuesday, October 17, 7:30-8:45 a.m. Central

Prime participants: Ben Urick, Health Outcomes Research Principal, Prime Therapeutics; Kyle Verley, Director of Network Management, Prime Therapeutics

Rare Disease Spotlight: Hereditary Angioedema Treatment Advances, Patient Value, and Access to Care

Tuesday, October 17, 7:30 – 8:45 a.m. Central

Prime Participants: Sneha Sharma, Director, Medical Pharmacy Strategy, MRx 

Improving Treatment Access for Spinal Muscular Atrophy: How Managed Care Strategies Can Ease Clinical and Caregiver Burden

Date/time: Tuesday, October 17, 10:30-12:30 p.m. Central

Prime participants: YuQian Liu, Senior Director, Clinical Account Services, Magellan Rx

Managed Care Oncology Perspectives: CAR T-cells vs BiTEs

Date/time: Tuesday, October 17, 2:15-3:30 p.m. Central

Prime participants: Michelle Pannone-Booth, Senior Director, Account Services, Magellan Rx; Simone Ndujiuba, Product Development, Director of Clinical Oncology, Magellan Rx 

Award-winning Research Supporting the Managed Care Pharmacy Agenda

Date/time: Tuesday, October 17, 2:15-3:30 p.m. Central

Prime participants: Nicholas Friedlander, Clinical Program Pharmacist, Prime Therapeutics

Biosimilar Operational Readiness: Managed Care Stakeholder Response to Market Expansion Impact

Date/time: Wednesday, October 18, 8:45 a.m.-10-:00 a.m. Central

Prime participants: Prerak Parikh, Director, Medical Pharmacy Strategy, Magellan Rx 

Navigating NASH: A Discussion on Clinical Background, Patient Advocacy and Managed Care Considerations

Date/time: Wednesday, October 18, 8:45-10:00 a.m. Central

Prime participants: Brian MacDonald, Senior Director, Clinical Project and Program Management, Magellan Rx 

Gene Therapies: Forecasting Potential Candidates Using Medical Pharmacy Claims Data

Date/time: Wednesday, October 18, 3:30-4:45 p.m. Central

Prime participants: Pat Gleason, AVP of Health Outcomes, Prime Therapeutics